Clinical trials: Stage II Chronic Lymphocytic Leukemia
Leukemia, Lymphoma
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Biological therapies such as denileukin diftitox may be able to deliver cancer-killing substances directly to non-Hodgkin's lymphoma cells.
- Trial name
- NCT00026429
- Testing
- denileukin diftitox
- Where
- 6 sites in United States
- Sponsor
- Pharmatech Oncology
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
- Trial name
- NCT03960840
- Testing
- Rapcabtagene autoleucel single agent, Ibrutinib
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 218 people
- Sponsor
- Novartis Pharmaceuticals
AML, Advanced MDS
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
The purpose of Phase I of this study is to test the safety and tolerability of the investigational drug, OTS167, and that of Phase II of this study is to confirm the potential response benefit of OTS167.
- Conditions
- AML, Advanced MDS, ALL, Advanced CML
- Trial name
- NCT02795520
- Testing
- OTS167IV
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- OncoTherapy Science, Inc.
Chronic Lymphocytic Leukemia
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
This is an open label, Phase I/II, dose escalation research study of an investigational product called lumiliximab, given with FDA (Food and Drug Administration) approved products fludarabine, cyclophosphamide, and rituximab…
- Trial name
- NCT00103558
- Testing
- Lumiliximab with FCR
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Biogen
Non-Hodgkins Lymphoma, B-cell Lymphoma
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
- Conditions
- Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT01647971
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The primary purpose of this study is to evaluate the safety, toxicities, dosage and response rate for an investigational drug, motexafin gadolinium, administered to patients with chronic lymphocytic leukemia or small lymphocytic…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Leukemia, Lymphoma
- Trial name
- NCT00290004
- Testing
- motexafin gadolinium
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pharmacyclics LLC.
Lymphocytic Leukemia, Chronic
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65…
- Trial name
- NCT01263704
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 12 sites in Israel
- Volunteers
- 42 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphocytic, Chronic
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)
- Trial name
- NCT00055146
- Testing
- ONTAK
- Where
- 14 sites in United States, Argentina and 3 more
- Volunteers
- 41 people
- Sponsor
- Eisai Inc.
Chronic Myelogenous Leukemia
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
This study is composed of Phase I and Phase II part. Phase I part: The objective is to evaluate the safety of BMS-354825 in subject with chronic phase Chronic Myelogenous Leukemia (CML).
- Trial name
- NCT00337454
- Testing
- Dasatinib
- Where
- 21 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Bristol-Myers Squibb
Lymphocytic Leukemia, Chronic
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of (obinutuzumab) RO5072759 in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT02053610
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
SPC2996 in Chronic Lymphocytic Leukaemia
The purpose of this study is to determine whether SPC2996 is effective and safe in the treatment of Chronic Lymphocytic Leukaemia (CLL)
- Trial name
- NCT00285103
- Testing
- SPC2996
- Where
- 12 sites in United States, Denmark and 2 more
- Volunteers
- 46 people
- Sponsor
- Santaris Pharma A/S